Saturday, May 31st, 2014

Poster Presentation: General Poster Session

Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets

of therapy

Time / Location: 8:00 am – 11:45 am / S Hall A2

Abstract / Poster Number: 4142 / #229

[View Abstract]

 

Poster Presentation: General Poster Session

BATTLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC)

Time / Location: 1:15 pm – 5:00 pm / S Hall A2

Abstract / Poster Number: 8042 / #223

Collaborator: The University of Texas MD Anderson

Cancer Center

[View Abstract]

 

Poster Presentation: General Poster Session

Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of

lung carcinoma

Time / Location: 1:15 pm – 5:00 pm / S Hall A2

Abstract / Poster Number: 8049 / #230

[View Abstract]

 

Poster Presentation: General Poster Session

Effect of clinical NGS-based cancer genomic profiling on physician treatment decisions in advanced solid tumors

Time / Location: 1:15 pm – 5:00 pm / S Hall A2

Abstract / Poster Number: 11109 / #391

Collaborator: Comprehensive Cancer Centers of Nevada

[View Abstract]

 

Poster Presentation: General Poster Session

Targeted next-generation sequencing (NGS) of carcinoma of unknown primary site (CUP): Actionable genomic alterations (GA) and new routes to targeted therapies

Time / Location: 1:15 pm – 5:00 pm / S Hall A2

Abstract / Poster Number: 11048 / #330

[View Abstract]

 

 

Sunday, June 1st, 2014

Poster Presentation: General Poster Session

PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response

Time / Location: 8:00 am – 11:45 am / S Hall A2

Abstract / Poster Number: 2606 / #69

Collaborator: The University of Texas MD Anderson

Cancer Center

[View Abstract]

 

 

Monday, June 2nd, 2014

Poster Presentation: Poster Highlights Session

Clinical application of comprehensive next-generation sequencing-based genomic profiling for identification of actionable genomic alterations in pediatric solid tumors and hematolymphoid malignancies: The Foundation Medicine pediatric experience

Time / Location: 8:00 am – 11:45 am / S Hall A2

Abstract / Poster Number: 10035 / #336

[View Abstract]

 

Poster Presentation: Poster Highlights Session

Next-generation sequencing (NGS)-based profiling of pancreatic acinar cell carcinoma for identification of a recurrent SND1-BRAF fusion

Time / Location: 8:00 am – 11:00 am / S405

Abstract / Publication #: 11029 / #18

[View Abstract]

 

Poster Presentation: Poster Highlights Session

Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC)

Time / Location: 8:00 am – 11:00 am / E354b

Abstract / Poster Number: 5536 / #26

Collaborator: AstraZeneca

[View Abstract]

 

Poster Presentation: Poster Highlights Session

Next-generation sequencing (NGS) in relapsed/refractory triple-negative breast cancer (TNBC) in Israel

Time / Location: 1:15 pm – 4:15 pm / E354b

Abstract / Poster Number: 1028 / #21

Collaborator: Teva Pharmaceuticals

[View Abstract]

 

Poster Presentation: General Poster Session

Evidence of PIK3CA and TP53 co-mutation in breast cancer identification on next-generation sequencing (NGS) of ERBB2 (HER2)-amplified residual disease following preoperative anti-HER2 therapy

Time / Location: 8:00 am – 11:45 am / S Hall A2

Abstract / Poster Number: 625 / #89

Collaborator: Texas Oncology

[View Abstract]

 

Poster Presentation: General Poster Session

Estrogen receptor-positive (ER+) metastatic breast cancer (MBC) patients (pts) with extreme responses (ERs) to capecitabine having tumors with genomic alterations in DNA repair and chromatin remodeling genes

Time / Location: 8:00 am – 11:45 am / S Hall A2

Abstract / Poster Number: 555 / #19

Collaborator: Texas Oncology-Baylor Charles A. Sammons Cancer Center

[View Abstract]

 

Poster Presentation: General Poster Session

Next-generation sequencing to identify molecular alterations in DNA repair and chromatin maintenance genes associated with pathologic complete response (pT0) to neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in muscle-invasive bladder cancer (MIBC)

Time / Location: 1:15 pm – 5:00 pm / S Hall A2

Abstract / Poster Number: 4538 / #106

Collaborator: Fox Chase Cancer Center

[View Abstract]

 

Oral Presentation: Clinical Science Symposium

Whole-exome and targeted sequencing of angiosarcomas: Target identification and treatment implications

Time / Location: 2:03 pm – 2:15 pm / S406

Abstract: 10512

Collaborator: The University of Texas MD Anderson

Cancer Center

[View Abstract]

 

Oral Presentation: Oral Abstract Session

Comprehensive genomic profiling of solid tumors from 677 adolescents and young adults for revealing a distinct spectrum of targetable genomic alterations

Time / Location: 5:24 pm – 5:36 pm / S100bc

Abstract: 11008

[View Abstract]

 

 

 

 

Tuesday, June 3rd, 2014

Poster Presentation: Poster Highlights Session

Rictor amplification to define a novel and unique subset of lung cancer patients

Time / Location: 8:00 am – 11:00 am / E354b

Abstract / Poster Number: 8027 / #42

Collaborator: Columbia University Medical Center

[View Abstract]

Poster Presentation: Poster Highlights Session

Next-generation sequencing (NGS) to identify actionable genomic alterations (GA) in “pan-negative” lung adenocarcinomas (ADC) from patients with no smoking or a light smoking (NS/LS) history

Time / Location: 8:00 am – 11:00 am / E354b

Abstract / Poster Number: 8029 / #44

Collaborator: Memorial Sloan-Kettering Cancer Center

[View Abstract]